Compare AbbVie Inc (ABBV) vs AST SpaceMobile Inc (ASTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs AST SpaceMobile Inc — how do they compare? AbbVie Inc trades at $249.83 (market cap $438.19B), while AST SpaceMobile Inc trades at $71.32 (market cap $20.54B). The key difference: AbbVie Inc is far larger — about 21.3× AST SpaceMobile Inc's market cap, and AbbVie Inc pays a 2.79% dividend while AST SpaceMobile Inc pays none. Which is the better fit depends on your goals.
| ABBV | ASTS | |
|---|---|---|
Market Cap | $438.19B | $20.54B |
Sector | Health | Media |
52-Week High | $263.58 | $133.09 |
52-Week Low | $197.38 | $36.91 |
Enterprise Value | $502.45B | $21.25B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $250.50, up 1.81% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and robust revenue growth, driven by Skyrizi and Rinvoq, highlight fundamental strength. The stock is supported by a 70.73% buy rating from analysts and a consensus price target of $281.33, with positive news flow from clinical trial results and institutional buying.
The outlook remains positive with earnings growth and dividend sustainability, though risks include patent cliffs in the 2030s and competitive pressures. Valuation metrics like a P/E of 70.05 suggest premium pricing, but operational cash flow of $19.03B in 2025 supports continued investment and shareholder returns.
AST SpaceMobile (ASTS) trades at $71.94, up 6.8% on the day, reflecting strong momentum despite recent earnings misses. The stock shows a bullish technical signal with key resistance at $73 and support at $69. Fundamentally, revenue grew to $71M in 2025, but net losses persist at -$342M, with a negative net margin of -482.17%. The company maintains a $1.3B backlog and raised its 2026 revenue guidance to $150M-$200M, indicating growth potential amid high cash burn.
Outlook: ASTS offers speculative upside driven by satellite network expansion and partnerships, with a consensus price target of $85.45 (19% upside). Risks include sustained losses, execution delays, and high valuation (P/S of 230.94). Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →
